Background Cancer patients have been reported to be at higher risk of COVID-19 complications
and deaths. We report the characteristics and outcome of patients diagnosed with …

Background Concerns have emerged about the higher risk of fatal coronavirus disease 2019
(COVID-19) in cancer patients. In this article, we review the experience of a comprehensive …

Background Aging is an important risk factor for cancers and is associated with poor prognosis.
Weakness of the immune system, also called immunosenescence may occur with older …

Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic
tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 …

Simple Summary The Lung Immune Prognostic Index (LIPI) is a score that combines pretreatment
dNLR (neutrophils/(leukocytes − neutrophils) and lactate dehydrogenase (LDH) and is …

Les points de contrôle du système immunitaires sont des récepteurs qui interviennent dans
la modulation de l’activation des cellules immunitaires afin de limiter la durée et l’intensité de …

Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several
types of cancer. Novel patterns of response and progression have been described with anti‐…

Background Immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy
(CT) are the current standard of therapy in several cancer types. Patients (pts) with lung …

Background Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1)
monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. …

Following the results of the IMpassion130 trial, an early access program (EAP) was opened
in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (…